Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

601. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. (Abstract)

Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Anticoagulation may improve survival in patients with cancer through an antitumor effect in addition to the perceived antithrombotic effect.To evaluate the efficacy and safety of parenteral anticoagulants in patients with cancer with no therapeutic or prophylactic indication for anticoagulation.A comprehensive search included (1) an electronic search (February 2010 (...) ) of the following databases: Cochrane Central Register of Controlled Trials (CENTRAL) Issue 1, 2010, MEDLINE, EMBASE and ISI the Web of Science; (2) handsearch of conference proceedings; (3) checking of references of included studies; and (4) use of the 'related citation' feature in PubMed.Randomized controlled trials (RCTs) assessing the benefits and harms of parenteral anticoagulation in patients with cancer but no therapeutic or prophylactic indication for anticoagulation.Using a standardized form we

2011 Cochrane

602. Parenteral anticoagulants for the treatment of atrial fibrillation: a systematic review

Parenteral anticoagulants for the treatment of atrial fibrillation: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2011 PROSPERO

603. Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis

Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2011 PROSPERO

604. Oral anticoagulation with warfarin - 4th edition

Oral anticoagulation with warfarin - 4th edition Guidelines on oral anticoagulation with warfarin – fourth edition - Keeling - 2011 - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. guideline Free Access Guidelines on oral anticoagulation with warfarin – fourth edition (...) can be found at . The objective of this guideline is to provide healthcare professionals with clear guidance on the indications for and management of patients on warfarin. This guideline replaces the previous BCSH guidelines on oral anticoagulants ( ; ). 1. Indications for warfarin and recommended target international normalized ratio (INR) This guideline refers to target INRs rather than target ranges, although the target range is generally taken to be within 0·5 of the target, i.e. a target INR

2011 British Committee for Standards in Haematology

605. [Biology of haemostasis disorders: lupus anticoagulant detection]

[Biology of haemostasis disorders: lupus anticoagulant detection] Biologie des anomalies de l'hémostase : détection d'un anticoagulant de type lupique [Biology of haemostasis disorders: lupus anticoagulant detection] Biologie des anomalies de l'hémostase : détection d'un anticoagulant de type lupique [Biology of haemostasis disorders: lupus anticoagulant detection] Haute Autorité de Santé Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Haute Autorité de Santé. Biologie des anomalies de l'hémostase : détection d'un anticoagulant de type lupique. [Biology of haemostasis disorders: lupus anticoagulant detection] . Paris: Haute Autorité de Santé (HAS). 2011 Authors' objectives The National Salaried Workers' Health Insurance Fund (CNAMTS) asked HAS to assess the value of the different laboratory tests for haemostasis abnormalities

2011 Health Technology Assessment (HTA) Database.

606. The dental patient on oral anticoagulant medication: a literature review

The dental patient on oral anticoagulant medication: a literature review The dental patient on oral anticoagulant medication: a literature review The dental patient on oral anticoagulant medication: a literature review Kosyfaki P, Att W, Strub JR CRD summary This review concluded that different anticoagulation strategies were associated with varying complications, during dental treatment. There was insufficient evidence to determine the safest successful dental treatment. The authors (...) ’ conclusions were suitably cautious and appropriate, reflecting the limited evidence available. Authors' objectives To evaluate the relationship between anticoagulant medication and dental treatment. Searching PubMed was searched for relevant English-language publications from 1988 to October 2010. Search terms were reported. High-yield journals (not specified) and relevant bibliographies were manually screened. Study selection Eligible for inclusion were studies assessing the relationship between oral

2011 DARE.

607. Safe and Effective Anticoagulation in the Outpatient Setting

Safe and Effective Anticoagulation in the Outpatient Setting Evidence-based Synthesis Program Safe and Effective Anticoagulation in the Outpatient Setting: A Systematic Review of the Evidence Department of Veterans Affairs Health Services Research & Development Service February 2011 Investigators: Principal Investigators: Hanna E. Bloomfield, MD, MPH Brent C. Taylor, PhD, MPH Co-Investigators: Ange Krause, MD Preetham Reddy, MD Research Associates: Nancy Greer, PhD Roderick MacDonald, MS (...) Indulis Rutks, BA Prepared for: Department of Veterans Affairs Veterans Health Administration Health Services Research & Development Service Washington, DC 20420 Prepared by: VA Evidence-based Synthesis Program (ESP) Center Center for Chronic Disease Outcomes Research Minneapolis VA Medical Center Minneapolis, MN Timothy J. Wilt, MD, MPH, Directori Safe and Effective Anticoagulation in the Outpatient Setting Evidence-based Synthesis Program This report is based on research conducted by the Evidence

2011 Veterans Affairs Evidence-based Synthesis Program Reports

608. Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement (Abstract)

Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement Self-management improves oral anticoagulation control. Here we provide data of a preplanned interim analysis of very low-dose early self-controlled anticoagulation.In a prospective, randomized, multicenter trial, 1,137 patients performed low-dose international normalized ratio (INR) self-management with a target INR range of 1.8. to 2.8 for aortic valve replacement

2011 EvidenceUpdates Controlled trial quality: uncertain

609. A Synthesis of the Evidence: Safe and Effective Anticoagulation in the Outpatient Setting

A Synthesis of the Evidence: Safe and Effective Anticoagulation in the Outpatient Setting Management Briefs Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs Health Services Research & Development Management Briefs Management eBriefs: Provide VA senior managers with results from VA Health Services Research in a concise and timely manner. , April 2019, Issue 152 , March 2019, Issue 151

2011 Veterans Affairs - R&D

610. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. Full Text available with Trip Pro

Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. To determine how length of anticoagulation and clinical presentation of venous thromboembolism influence the risk of recurrence after anticoagulant treatment is stopped and to identify the shortest length of anticoagulation that reduces the risk of recurrence to its lowest (...) level.Pooled analysis of individual participants' data from seven randomised trials.Outpatient anticoagulant clinics in academic centres.2925 men or women with a first venous thromboembolism who did not have cancer and received different durations of anticoagulant treatment.First recurrent venous thromboembolism after stopping anticoagulant treatment during up to 24 months of follow-up.Recurrence was lower after isolated distal deep vein thrombosis than after proximal deep vein thrombosis (hazard ratio

2011 BMJ

611. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. (Abstract)

Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. A number of basic research and clinical studies have led to the hypothesis that oral anticoagulants may improve the survival of patients with cancer through an antitumor effect in addition to their antithrombotic effect.To evaluate the efficacy and safety of oral anticoagulants in patients with cancer with no therapeutic or prophylactic indication for anticoagulation.A (...) comprehensive search for studies of anticoagulation in cancer patients including (1) a February 2010 electronic search of the following databases: Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), MEDLINE, EMBASE, ISI the Web of Science; (2) hand search of the American Society of Clinical Oncology (starting with its first volume, 1982) and of the American Society of Hematology (starting with its 2003 issue); (3) checking of references of included studies; and (4) use

2010 Cochrane

612. Interventions other than anticoagulants and systemic antibiotics for prevention of central venous catheter-related infections in children with cancer. (Abstract)

Interventions other than anticoagulants and systemic antibiotics for prevention of central venous catheter-related infections in children with cancer. Use of central venous catheters (CVC) in treatment of children with cancer is associated with infective complications. Current evidence-based guidelines to prevent catheter-related infections are mainly relevant to the adult population. They are not cancer (especially not childhood cancer) specific. Two existing Cochrane reviews have looked (...) at prophylactic antibiotics and anticoagulants to prevent CVC-related infections.The primary objective was to find which interventions, if any, were effective in preventing CVC-related infections in children with cancer. Further objectives were to examine the effectiveness of each intervention in the following subgroups: implanted versus external catheters, haematological versus non-haematological malignancies, and in those receiving haematopoietic stem cell transplants (HSCT) versus no HSCT.We searched

2010 Cochrane

613. Safety of uninterrupted anticoagulation in patients requiring elective coronary angiography with or without percutaneous coronary intervention: a systematic review and metaanalysis (Abstract)

Safety of uninterrupted anticoagulation in patients requiring elective coronary angiography with or without percutaneous coronary intervention: a systematic review and metaanalysis Patients who are receiving vitamin K antagonist (VKA) therapy pose challenges when they require surgery or invasive procedures because the risk for bleeding during the procedure must be balanced against the risk of an atherothrombotic event if the VKA is interrupted. However, it may be possible to safely perform some (...) with or without PCI can be safely performed without interrupting VKA, the low methodologic quality of existing studies precludes any definitive conclusions. Randomized trials assessing different anticoagulation strategies are needed to establish evidence-based practice guidelines in this setting.

2010 EvidenceUpdates

614. Drug and dietary interactions of the new and emerging oral anticoagulants Full Text available with Trip Pro

Drug and dietary interactions of the new and emerging oral anticoagulants Oral warfarin is associated with extensive food and drug interactions, and there is a need to consider such interactions with the new oral anticoagulants (OACs) dabigatran etexilate, rivaroxaban and apixaban. A literature survey was conducted using PubMed, EMBASE and recent abstracts from thrombosis meetings to identify publications related to food, drug and dietary supplement interaction studies with dabigatran etexilate

2010 EvidenceUpdates

615. Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy. Full Text available with Trip Pro

Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy. Thromboembolic complications are much higher in pregnancy due to procoagulant changes. Heparin does not cross the placenta and the use of unfractionated heparin (UFH) is the current established practice in prophylaxis and treatment for thromboembolism in pregnancy.To compare the effectiveness of anticoagulant therapies for the treatment of deep vein thrombosis in pregnancy. The anticoagulant drugs included are UFH, low molecular (...) did not identify any eligible studies for inclusion in the review.We identified three potential studies; after assessing eligibility, we excluded all three as they did not meet the prespecified inclusion criteria. One study compared LMWH and UFH in pregnant women with previous thromboembolic events and, for most of these women, anticoagulants were used as thromboprophylaxis. There were only three women who had a thromboembolic event during the current pregnancy and it was unclear whether

2010 Cochrane

616. Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures

Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted (...) anticoagulant therapy for simple oral surgical procedures Ralph Rosenblum Jr. DDS, MHA . Overview Systematic Review Conclusion Patients taking oral anticoagulant therapy [OAT] did not experience a higher risk of post-operative bleeding compared to patients not on OAT or OAT patients who discontinue therapy following simple oral surgical procedures. Critical Summary Assessment The findings suggest that it is not necessary to discontinue OAT for simple oral surgical procedures. Evidence Quality Rating Good

2010 ADA Center for Evidence-Based Dentistry

617. Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures

Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted (...) anticoagulant therapy for simple oral surgical procedures Ralph Rosenblum Jr. DDS, MHA . Overview Systematic Review Conclusion Patients taking oral anticoagulant therapy [OAT] did not experience a higher risk of post-operative bleeding compared to patients not on OAT or OAT patients who discontinue therapy following simple oral surgical procedures. Critical Summary Assessment The findings suggest that it is not necessary to discontinue OAT for simple oral surgical procedures. Evidence Quality Rating Good

2010 ADA Center for Evidence-Based Dentistry

618. Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures

Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted (...) anticoagulant therapy for simple oral surgical procedures Ralph Rosenblum Jr. DDS, MHA . Overview Systematic Review Conclusion Patients taking oral anticoagulant therapy [OAT] did not experience a higher risk of post-operative bleeding compared to patients not on OAT or OAT patients who discontinue therapy following simple oral surgical procedures. Critical Summary Assessment The findings suggest that it is not necessary to discontinue OAT for simple oral surgical procedures. Evidence Quality Rating Good

2010 ADA Center for Evidence-Based Dentistry

619. Chief of Service Rounds: Should You Always Stop Anticoagulating a Bleeding Patient?

Chief of Service Rounds: Should You Always Stop Anticoagulating a Bleeding Patient? Chief of Service Rounds: Should You Always Stop Anticoagulating a Bleeding Patient? – Clinical Correlations Search Chief of Service Rounds: Should You Always Stop Anticoagulating a Bleeding Patient? January 20, 2010 6 min read | | Sites We Follow: Useful Links: Questions? Comments? Contact us! © New York University. All rights reserved. Electronic ISSN 1944-0030. The content of this site is intended for health

2010 Clinical Correlations

620. Oral Dabigatran Etexilate: an Emerging Alternative to Conventional Anticoagulation Therapy

Oral Dabigatran Etexilate: an Emerging Alternative to Conventional Anticoagulation Therapy "Oral Dabigatran Etexilate: an Emerging Alternative to Conventional Ant" by Megan C. Merritt < > > > > > Title Author Date of Graduation 8-14-2010 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor James Ferguson PA-C, MPH Second Advisor Annjanette Sommers MS, PAC Third Advisor Rob Rosenow PharmD, OD Rights . Abstract Background: Thromboembolic events (...) are a substantial healthcare concern, both in hospital and community settings. The current standards of anticoagulation, heparin and warfarin, have well-demonstrated efficacy, but come with sizeable drawbacks. Heparin requires parenteral administration, and carries the risk of osteoporosis and severe thrombocyotopenia. Warfarin, the only oral anticoagulant available, gives inconsistent results, and thus requires frequent laboratory monitoring and adjustment. A fixed-dose oral anticoagulant would ease the burden

2010 Pacific University EBM Capstone Project